Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cetuximab 4Radiosurgery 3Nivolumab 3Ipilimumab 3pembrolizumab 2Vorinostat 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Magnetic Resonance Spectroscopy 2Lapatinib 2Dasatinib 2Cisplatin 2CTLA-4 Antigen 2Bevacizumab 2temsirolimus 1ispinesib 1eribulin 1dehydroftorafur 1apalutamide 1amivantamab 1alectinib 1Specimen Handling 1Sorafenib 1Sirolimus 1Platinum 1Pilocarpine 1Pemetrexed 1Oral Hygiene 1NVP-BKM120 1Moxibustion 1MK 2206 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Salivary Gland Neoplasms × ispinesib × Clear all
NCT00095628 2017-03-06

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 10 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡